Asylia Therapeutics

Recent Finacing

Series A

Recent Raise

$14.5M

Asylia Therapeutics develops immune-modulating therapies that target extracellular HSP70 to enhance antigen presentation and activate dendritic cells and cytotoxic T-cell responses for cancer and autoimmune diseases.

Founded 2019

Texas, United States

1-10

Private

asyliatx.com

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

Financials

$14.5M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at Asylia Therapeutics.